https://cslide.ctimeetingtech.com/gi2025/attendee/
Post# of 152322
(Total Views: 596)
Posted On: 05/05/2025 12:55:33 PM
https://cslide.ctimeetingtech.com/gi2025/atte...tation/886
134eP - Observed Survival Following Treatment With Leronlimab In Patients With Metastatic Colorectal Cancer.
Session Name
Poster display session and coffee break
Room
Foyer
Date
Fri, 04.07.2025
Lecture Time
15:30 - 15:30
Speakers
Ari Baron (San Francisco, United States of America)
Just found this.
This is a scientific poster presentation at a medical conference organized by the European Society for Medical Oncology
(ESMO), focusing on gastrointestinal cancers.
The presentation discusses a study or clinical data related to Leronlimab.
Who is Ari Baron?
Ari Baron, MD, is a medical oncologist based in San Francisco, California.
The ESMO 2025 poster (134eP) on Leronlimab for metastatic colorectal cancer is most likely based on early data from the new Phase 2 trial (NCT06699835)? Maybe focus on MSS mCRC and OS endpoints.
Preliminary results (e.g., ORR, interim survival) are plausible by July 2025, though the data may be too soon bc technically we didn’t start it right.
From chat.
“Ari Baron's involvement as a colorectal cancer specialist and the trial's start in early 2025 make it probable that the poster reports new data from the Phase 2 trial, likely interim results after ~6 months.”
I think chats wrong this is old data but we don’t know.
Think this pushes the market over the edge today lol another ESMO event for CRC!!!!! Screw the shorts.
134eP - Observed Survival Following Treatment With Leronlimab In Patients With Metastatic Colorectal Cancer.
Session Name
Poster display session and coffee break
Room
Foyer
Date
Fri, 04.07.2025
Lecture Time
15:30 - 15:30
Speakers
Ari Baron (San Francisco, United States of America)
Just found this.
This is a scientific poster presentation at a medical conference organized by the European Society for Medical Oncology
(ESMO), focusing on gastrointestinal cancers.
The presentation discusses a study or clinical data related to Leronlimab.
Who is Ari Baron?
Ari Baron, MD, is a medical oncologist based in San Francisco, California.
The ESMO 2025 poster (134eP) on Leronlimab for metastatic colorectal cancer is most likely based on early data from the new Phase 2 trial (NCT06699835)? Maybe focus on MSS mCRC and OS endpoints.
Preliminary results (e.g., ORR, interim survival) are plausible by July 2025, though the data may be too soon bc technically we didn’t start it right.
From chat.
“Ari Baron's involvement as a colorectal cancer specialist and the trial's start in early 2025 make it probable that the poster reports new data from the Phase 2 trial, likely interim results after ~6 months.”
I think chats wrong this is old data but we don’t know.
Think this pushes the market over the edge today lol another ESMO event for CRC!!!!! Screw the shorts.
(19)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼